ClinConnect ClinConnect Logo
Search / Trial NCT00250250

An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG

Launched by FERRING PHARMACEUTICALS · Nov 7, 2005

Trial Information

Current as of July 01, 2025

Completed

Keywords

ClinConnect Summary

Ferring Pharmaceuticals A/S has developed a new ZOMACTON 10 mg formulation. The formulation provides a higher concentration and thereby a smaller volume to be administered. ZomaJet Vision X is a needle-free injection system. It sends a thin jet of ZOMACTON through the skin and into the subcutaneous tissue without the use of a needle. The mode of administration is referred to as "transjection". By use of ZomaJet Vision X, both transjection and reconstitution of ZOMACTON 10 mg can be done without using a needle. The rationale of the study is to describe the local tolerability of the new ZOMAC...

Gender

ALL

Eligibility criteria

  • Subjects between the ages of 3 and 17 years (both inclusive) with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome. Subjects have for a minimum of 6 months prior to study enrolment been receiving growth hormone therapy

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs in various therapeutic areas, including reproductive health, urology, and gastrointestinal disorders. With a strong commitment to advancing healthcare through scientific excellence and patient-centered solutions, Ferring leverages its extensive expertise in hormone-related treatments and personalized medicine. The company actively engages in clinical research to develop safe and effective therapies, striving to improve the quality of life for patients worldwide while maintaining a focus on ethical practices and collaboration in the healthcare community.

Locations

Olomouc, , Czech Republic

Prague 10, , Czech Republic

Usti Nad Labem, , Czech Republic

Bordeaux, , France

Le Havre Cedex, , France

Amsterdam, , Netherlands

Patients applied

0 patients applied

Trial Officials

Clinical Development Support

Study Director

Ferring Pharmaceuticals

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials